Australia is carefully awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://safiyayyjg362025.lotrlegendswiki.com/2561768/retatrutide_australia_a_potential_hope_for_obesity_treatment